← Back to headlines
SAB Biotherapeutics (SABS) and Breakthrough T1D Award Research Grant for SAB-142 Assessment
SAB Biotherapeutics (SABS) and Breakthrough T1D have been awarded a research grant for the assessment of SAB-142. This funding will support further study into the therapeutic potential of SAB-142.
15 Jul, 15:43 — 15 Jul, 15:43
Sources
Showing 1 of 1 sources
